$JNJ $LEGN Janssen Biotech, a Johnson &amp; Johnson(JNJ) subsidiary, said in a Thursday filing that it is on track to file a biologics license application to the US Food and Drug Administration by the end of the year for the development of JNJ-4528 to treat multiple myeloma.